Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arzneiwerk AG VIDAHAM:TLIK 40 5-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates HAM:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 99 Medical Distribution companies, Arzneiwerk AG VIDA ranks worse than 1010100% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Arzneiwerk AG VIDA's 5-Year RORE % for the quarter that ended in Mar. 2026 was 0.00%.
The industry rank for Arzneiwerk AG VIDA's 5-Year RORE % or its related term are showing as below:
HAM:TLIK's 5-Year RORE % is not ranked *
in the Medical Distribution industry.
Industry Median: 5.04 * Ranked among companies with meaningful 5-Year RORE % only.
Arzneiwerk AG VIDA (HAM:TLIK) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Arzneiwerk AG VIDA 5-Year RORE % Related Terms
Arzneiwerk AG VIDA 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Arzneiwerk AG VIDA's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:TLIK vs MCK, COR, CAH: 5-Year RORE % Comparison
For the Medical Distribution subindustry, Arzneiwerk AG VIDA's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arzneiwerk AG VIDA 5-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Arzneiwerk AG VIDA's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Arzneiwerk AG VIDA (HAM:TLIK) has a 5-Year RORE % of 0.00 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Arzneiwerk AG VIDA and its competitors. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 99 companies in the Medical Distribution industry.
Is Arzneiwerk AG VIDA's 5-Year RORE % too high?
Arzneiwerk AG VIDA's current 5-Year RORE % is 0.00. Based on the distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's 5-Year RORE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 99 companies for 5-Year RORE %. This places Arzneiwerk AG VIDA in the lower half of its industry. The industry median 5-Year RORE % is 5.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Distribution company?
The median 5-Year RORE % among Medical Distribution companies is 5.04, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Arzneiwerk AG VIDA and its competitors. For the Medical Distribution industry, the median 5-Year RORE % is 5.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (HAM:TLIK) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Arzneiwerk AG VIDA (HAM:TLIK), the current 5-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score
Get the complete analysis for HAM:TLIK
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:TLIK has been successfully added to your 
